Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis

Corporate Breaking News

Home : Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis

Jun 14 2019	Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
MUMBAI, India and PRINCETON, N.J., June 14, 2019 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced interim results from a Phase 2...


Source:https://www.prnewswire.com:443/news-releases/sun-pharma-announces-late-breaking-phase-2-data-showing-potential-of-ilumya-tildrakizumab-asmn-to-improve-joint-and-skin-symptoms-of-psoriatic-arthritis-300867695.html

Related News
» Sprint's True Mobile 5G Network Adds Samsung Galaxy S10 5G on June 21 » Fraport Traffic Figures - May 2019: Frankfurt Airport Reports Solid Growth